Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Tuesday 01 March, 2022

Omega Diagnostics Gp

Result of Open Offer

RNS Number : 1019D
Omega Diagnostics Group PLC
01 March 2022
 

THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA THE REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Result of Open Offer

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, today announces the results of its Open Offer.

On 11 February 2022, Omega announced its intention to raise gross proceeds of up to £7 million by way of a Placing, Subscription and Open Offer (together the "Fundraising"), all at an issue price of 5 pence per New Ordinary Share.

The Open Offer closed for acceptances at 11:00 a.m. on 28 February 2022. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 6,468,652 New Ordinary Shares and has also received applications from Qualifying Shareholders under the Excess Application Facility in respect of 3,085,559 New Ordinary Shares. In aggregate this totals 9,554,211 New Ordinary Shares, representing approximately 23.5 per cent. of the Open Offer Shares.  Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements as well as those applied for under the Excess Application Facility.

Accordingly, a total of 109,554,211 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 98,700,000 New Ordinary Shares will be issued pursuant to the Placing, 1,300,000 New Ordinary Shares will be issued pursuant to the Subscription and 9,554,211 New Ordinary Shares will be issued pursuant to the Open Offer (the "Open Offer Shares"). This brings the gross proceeds of the Fundraising to £5.48 million before expenses.

 

General Meeting

The Fundraising remains conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held on 7 March 2022 (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 8 March 2022 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 31 March 2022).

The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 11 February 2022.

 

For further information, please contact:

Enquiries

 

Omega Diagnostics Group PLC 

www.omegadiagnostics.com

Jag Grewal, Chief Executive Officer

via Walbrook PR

Chris Lea, Chief Financial Officer

 

 

 

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

 

Alice Lane/ Charlotte Sutcliffe (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

     

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROIUWVBRUSUUUAR

a d v e r t i s e m e n t